VANCOUVER, Sept. 4, 2012 /CNW/ - iCo Therapeutics Inc. ("iCo" or "the
Company") (TSX-V: ICO), today announced it will be presenting at the
Rodman & Renshaw 2012 Annual Global Investment Conference in New York
Management will deliver the Company presentation to conference attendees
on Tuesday, September 11 at 1:35 PM ET in the North Foyer at the
Waldorf Astoria Hotel.
Andrew Rae, President & CEO of iCo, commented that, "This conference
provides us with the opportunity to highlight our clinical pipeline and
specifically our lead candidate iCo-007 in the iDEAL study for Diabetic
Macular Edema, from which we expect to announce interim data before the
end of the year."
More than 300 public and private companies from around the world are
registered to present in front of an audience of over 3,000 attendees.
Newt Gingrich, 58th Speaker of the U.S. House of Representatives, will
open the Conference as the Keynote Speaker on Monday, September 10.
About iCo Therapeutics
iCo Therapeutics Inc. is a Vancouver-based reprofiling company focused
on redosing or reformulating drugs with clinical history for new or
expanded indications. iCo has exclusive worldwide rights to three
products: iCo-007, in Phase 2 for the treatment of Diabetic Macular
Edema (DME); iCo-008 (Bertilimumab), a product with Phase 2 clinical
history to be developed for sight threatening diseases; and an oral
Amphotericin B delivery system for life-threatening infectious
diseases. Immune Pharmaceuticals licensed systemic rights to iCo-008 in
June 2011. iCo trades on the TSX Venture Exchange under the symbol
"ICO". For more information, visit the Company website at: www.icotherapeutics.com.
No regulatory authority has approved or disapproved the content of this
release. The TSX Venture Exchange does not accept responsibility for
the adequacy or accuracy of this release.
Forward Looking Statements
Certain statements included in this press release may be considered
forward-looking. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results,
performance or achievements to be materially different from those
implied by such statements, and therefore these statements should not
be read as guarantees of future performance or results. All
forward-looking statements are based on iCo's current beliefs as well
as assumptions made by and information currently available to iCo and
relate to, among other things, anticipated financial performance,
business prospects, strategies, regulatory developments, market
acceptance and future commitments. Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak only as
of the date of this press release. Due to risks and uncertainties,
including the risks and uncertainties identified by iCo in its public
securities filings; actual events may differ materially from current
expectations. iCo disclaims any intention or obligation to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
SOURCE: iCo Therapeutics Inc.
For further information:
Mr. John Meekison, CFO
604-602-9414 x 224
Michael Moore, Investor Relations
David Waldman/Klea Theoharis